CSI Laboratories Announces Equity Stake Acquisition by Synergy Capital Investments

07:30 EDT 9 Jul 2019 | Businesswire
CSI Laboratories

Equity Investment Denotes Strong Profitability and Continued Growth

CSI Laboratories (CSI) and Synergy Capital Investments (Synergy) today announced the transition of a convertible note to equity stake in CSI, a state of the art, specialized cancer diagnostic center.

“The security purchase agreement, originally issued in 2017, supported a significant transformation around revenue cycle, sales and operational management that improved our profitability,” said Chief Executive Officer and Chief Financial Officer, Chris Wicker. “The note positioned CSI to expand capabilities through the implementation of cutting-edge informatics and the addition of the second testing facility in Jupiter, FL that opened earlier in 2019. We are very pleased to continue our partnership with Synergy as a shareholder and build on CSI’s robust performance.”

CSI executed a considerable financial turnaround in the past two years, and the financial outlook is positive for sustained planned growth.

Munir Karimi, Chief Executive Officer of Synergy, assumes a seat on the Board of Directors of CSI. Said Karimi, “We have been working closely with the CSI team for the past couple of years. This is an excellent time to participate on the equity side given their strong financial performance, outstanding executive guidance, and medical thought leadership. The investment reflects our excitement and optimism for CSI’s continued momentum and reinforces our support of CSI Laboratories.”


CSI Laboratories was founded in 1997 to provide a more client- and patient-focused model of cancer diagnostic testing for pathologists, community hospitals and their patients. CSI Laboratories offers flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, molecular genetics, next generation sequencing, and consultations to hematopathology and surgical pathology clients. It is independently owned and operated by medical professionals, providing expert diagnostic testing and rapid turnaround times for clients across the United States. CSI is a CLIA-certified and CAP-accredited cancer reference laboratory located in Alpharetta, GA. For more information, please visit


Synergy Capital Investments is an Atlanta, Georgia-based diversified private equity firm that specializes in the acquisition, joint venture, and management of small to mid-market operating businesses. Using capital investment and the strength of its network of advisors, investors, and partners, Synergy offers a specialized approach that drives the next level of strategic growth. Its investment portfolio includes real estate, healthcare, and retail operations. For more information, visit

Denise Reed


More From BioPortfolio on "CSI Laboratories Announces Equity Stake Acquisition by Synergy Capital Investments "

Quick Search

Relevant Topics

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...